AN0025 + Chemoradiation for Lung Cancer
Trial Summary
What is the purpose of this trial?
Primary* Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation)* Evaluate efficacy by progression-free survival (PFS), objective response rate (ORR), and time to death or distant metastasis (TTMD), Duration of response (DOR), Overall survival (OS) with the addition of AN0025 in both the consolidative and concurrent settings Exploratory* Evaluate pharmacokinetics of AN0025 in conjunction with chemoradiation, and then with durvalumab
Research Team
Salma Jabbour, MD
Principal Investigator
Rutgers Cancer Institute of New Jersey
Eligibility Criteria
This trial is for adults over 18 with Stage III Non-Small Cell Lung Cancer who can perform daily activities, have adequate organ function and lung capacity. They must not be pregnant or breastfeeding, agree to use contraception, and cannot have a second active cancer or severe allergies to the treatment components.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Chemoradiation
Participants receive AN0025 in combination with chemoradiation therapy
Consolidation
Participants receive durvalumab following chemoradiation
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AN0025
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
Adlai Nortye Biopharma Co., Ltd.
Industry Sponsor